Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vaxcyte (PCVX) Preferred Stock Liabilities (2019 - 2020)

Vaxcyte (PCVX) has 2 years of Preferred Stock Liabilities data on record, last reported at $80.2 million in Q1 2020.

  • On a quarterly basis, Preferred Stock Liabilities rose 112.76% to $80.2 million in Q1 2020 year-over-year; TTM through Mar 2020 was $80.2 million, a 112.76% increase, with the full-year FY2019 number at $160.3 million, up 325.32% from a year prior.
  • Preferred Stock Liabilities reached $80.2 million in Q1 2020 per PCVX's latest filing, down from $160.3 million in the prior quarter.
  • Over the last five years, Preferred Stock Liabilities for PCVX hit a ceiling of $160.3 million in Q4 2019 and a floor of $25.0 million in Q3 2019.